168 related articles for article (PubMed ID: 17785994)
1. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study.
Cazzaniga ME; Dogliotti L; Cascinu S; Barni S; Labianca R; Chiara S; Conte PF; Gasparini G; Pasetto L; Torri V
Oncology; 2006; 71(5-6):374-81. PubMed ID: 17785994
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
3. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
4. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
5. Markers of bone turnover do not predict bone metastases in breast cancer.
Seibel MJ; Koeller M; Van der Velden B; Diel I
Clin Lab; 2002; 48(11-12):583-8. PubMed ID: 12465741
[TBL] [Abstract][Full Text] [Related]
6. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of women with metastatic breast cancer: a descriptive study according to age group.
Manders K; van de Poll-Franse LV; Creemers GJ; Vreugdenhil G; van der Sangen MJ; Nieuwenhuijzen GA; Roumen RM; Voogd AC
BMC Cancer; 2006 Jul; 6():179. PubMed ID: 16824210
[TBL] [Abstract][Full Text] [Related]
8. Brain metastases in breast cancer: prognostic factors and management.
Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast carcinoma confined to bone: portrait of a clinical entity.
Briasoulis E; Karavasilis V; Kostadima L; Ignatiadis M; Fountzilas G; Pavlidis N
Cancer; 2004 Oct; 101(7):1524-8. PubMed ID: 15316943
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
12. Management of bone metastases in cancer: a review.
Selvaggi G; Scagliotti GV
Crit Rev Oncol Hematol; 2005 Dec; 56(3):365-78. PubMed ID: 15978828
[TBL] [Abstract][Full Text] [Related]
13. Metastatic bone tumors. Nonsurgical treatment. Outcome and survival.
Toma S; Venturino A; Sogno G; Formica C; Bignotti B; Bonassi S; Palumbo R
Clin Orthop Relat Res; 1993 Oct; (295):246-51. PubMed ID: 8403656
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
17. [Clinical results and prognostic factors of radiotherapy for bone metastases from breast cancer].
Yoden E; Murakami M; Kuroda Y; Kono K; Sasaki R
Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Jan; 59(1):27-33. PubMed ID: 10067313
[TBL] [Abstract][Full Text] [Related]
18. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
19. [Bone-related events in breast cancer].
Kurebayashi J
Clin Calcium; 2008 Apr; 18(4):447-54. PubMed ID: 18379025
[TBL] [Abstract][Full Text] [Related]
20. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
